All News

2019

May

Media Release / May 24, 2019

FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

Read More
Media Release / May 24, 2019

AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families

Read More
Media Release / May 24, 2019

AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Read More
Researchers in the lab
Story / May 24, 2019

Cancer research drives breast cancer treatment forward

Novartis team perseveres to develop more personalized approach to breast cancer therapy.

Read More
Media Release / May 23, 2019

Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event

Read More
Media Release / May 22, 2019

Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment

Read More
A doctor discusses different clinical trial options with a patient.
Story / May 17, 2019

Respiratory clinical trials: Putting patients at the heart of research

All treatments that exist today started with patients volunteering to participate in a study and healthcare professionals offering their expertise.

Read More
Media Release / May 16, 2019

Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

Read More
Featured News / May 15, 2019

SOLAR-1 NEJM Publication

Read More
Media Release / May 10, 2019

Novartis data at AAN show Gilenya® is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS

Read More

Pages

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More